Vital Signs: 02 December 2009 – PXS
December 1, 2009
Pharmaceutical company Pharmaxis Limited (PXS) today announced the results of the phase III trial of Bronchitol for the treatment of cystic fibrosis. Lung function increased for patients from 6.5% at the six month mark to 8% over the course of twelve months, while patients who were treated initially with a placebo saw lung capacity increase by over 20% when treatment was switched to Bronchitol. Bronchitol is designed to hydrate the airway surface of the lungs, and promote normal lung mucus clearance, the company said.
Leave a Reply